Literature DB >> 10022365

Methodological issues in estimating the cost of epilepsy.

C E Begley1, J F Annegers, D R Lairson, T F Reynolds.   

Abstract

Changes in treatment alternatives and the emphasis on cost containment and managed care have increased the interest in information on the cost of epilepsy. The last comprehensive cost study in the USA was in 1975. That study estimated the national cost of epilepsy at $3.6 billion for 2.1 million cases. On a per patient basis the 1975 figure represents $7440 in 1995 US dollars, $1150 (15%) for direct treatment-related costs and $6290 (85%) for indirect employment-related costs. Since then, various cost-of-illness (COI) studies in the USA and other countries have offered estimates ranging from $6000 to $15000 per patient per year, with percentages of direct and indirect cost varying greatly. To assist those interested in interpreting or producing cost information, this paper reviews the state of research on the cost of epilepsy and discusses several methodological issues. A comprehensive study begun in 1993 to update the 1975 estimates for the USA is also described. Recommendations are provided to stimulate discussion about the best methods to use in future research.

Entities:  

Mesh:

Year:  1999        PMID: 10022365     DOI: 10.1016/s0920-1211(98)00070-9

Source DB:  PubMed          Journal:  Epilepsy Res        ISSN: 0920-1211            Impact factor:   3.045


  6 in total

1.  Cost-of-illness studies: a guide to critical evaluation.

Authors:  Allison Larg; John R Moss
Journal:  Pharmacoeconomics       Date:  2011-08       Impact factor: 4.981

2.  Systematic review of economic burden of heart failure.

Authors:  Asrul Akmal Shafie; Yui Ping Tan; Chin Hui Ng
Journal:  Heart Fail Rev       Date:  2018-01       Impact factor: 4.214

3.  Economic evaluation of levetiracetam as an add-on therapy in patients with refractory epilepsy.

Authors:  Lucie Blais; Odile Sheehy; Jean-Marc St-Hilaire; Giles Bernier; Philippe Godfroid; Jacques J LeLorier
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 4.  Cost of epilepsy: a systematic review.

Authors:  Adam Strzelczyk; Jens Peter Reese; Richard Dodel; Hajo M Hamer
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

5.  Health care utilization and outpatient, out-of-pocket costs for active convulsive epilepsy in rural northeastern South Africa: a cross-sectional Survey.

Authors:  Ryan G Wagner; Melanie Y Bertram; F Xavier Gómez-Olivé; Stephen M Tollman; Lars Lindholm; Charles R Newton; Karen J Hofman
Journal:  BMC Health Serv Res       Date:  2016-06-28       Impact factor: 2.655

Review 6.  Direct and indirect costs and cost-driving factors in adults with tuberous sclerosis complex: a multicenter cohort study and a review of the literature.

Authors:  Johann Philipp Zöllner; Janina Grau; Felix Rosenow; Matthias Sauter; Markus Knuf; Gerhard Kurlemann; Thomas Mayer; Christoph Hertzberg; Astrid Bertsche; Ilka Immisch; Karl Martin Klein; Susanne Knake; Klaus Marquard; Sascha Meyer; Anna H Noda; Felix von Podewils; Hannah Schäfer; Charlotte Thiels; Laurent M Willems; Bianca Zukunft; Susanne Schubert-Bast; Adam Strzelczyk
Journal:  Orphanet J Rare Dis       Date:  2021-06-02       Impact factor: 4.123

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.